q&more
My watch list
my.chemie.de  
Login  
Translation

Translation

Innovations from the lab to commercial application

Prof. Dr. Arne Skerra (Technische Universität München, Lehrstuhl für Biologische Chemie)

The structure of the big chemical and pharmaceutical companies has changed. Traditional centralised research departments conducting fundamental research have fallen victim to economic considerations. In exchange, young, dynamic start-up enterprises are increasingly brightening up the scene. This boosts the development of new international co-operation models for the conversion of scientific ideas and findings into new products.

The biotech industry has developed into an established sector in Germany, among other countries; its business ideas originate primarily from universities or research institutes, which are put into practice by young scientists. Assisted by management and business plan seminars, the foundation of companies has become a serious alternative for bioscience graduates to conventional professional careers which have become increasingly rare due to the structural change in the industry. Public promotion programmes such as GO-Bio, EXIST and FLÜGGE support such initiatives at different stages.

This trend is progressively spilling over into other areas in chemistry, physics and engineering for which – considering the innovation and human potential – similarly fertile conditions are found at the universities. Admittedly, long time lines and high development effort as well as significant production costs are to be balanced against a highly variable intrinsic product value. In the case of biotech companies, the guarantee for return on investment is generally the prospect of later clinical approval for a lucrative blockbuster drug. This is in stark contrast to bulk production in the chemical industry: large-scale manufacturing of chemicals and polymers seen against low profit margins and high capital expenditure for technical equipment.

Nevertheless, this sector also offers opportunities for added value through highly innovative processes and/or refined goods and a business to business (B2B) model. Generating new know-how and patents is the actual
value driver for such start-up companies and gives them a right to exist beside large enterprises which increasingly focus on regulatory aspects (technical safety, regulatory approval), mass production for end consumers as well as sales and marketing. The high dynamics of innovation in a flat-hierarchy, highly flexible and pragmatic environment have led to a profitable job sharing between the biotech start-up scene and the pharmaceutical industry, for example. However, two aspects deserve attention in order not to hamper this ongoing development.

On the one hand, there is an early stage financing problem for advancing innovations by newly-formed companies. The gap between the seed phase, mostly financed by public funding bodies, and the start-up phase, which is focused on product development and expansion, has grown in the past few years. New mechanisms of co-operation between venture capital (VC) companies and private investors need to be found. While for the former an investment only attracts interest as from a certain financing volume and an already calculable stage of development of the technical innovation, the latter frequently take a higher risk and are more guided by the founders‘ personality; yet it is less of an incentive if private investors – including the founders of the company – get marginalised by venture capital in the course of subsequent financing rounds.

On the other hand, university intellectual property (IP) management requires overhauling. Although today most universities have their own technology transfer agencies and inventor offices, processes are frequently unduly bureaucratic and subject to unrealistic expectations of early profits. The revision of the German Employee Invention Act of 2002, which deprived university employees of their independence as inventors, was rather counter-productive. The majority of university IP – in contrast to technologically more focused large research organisations such as the Max Planck Society or Helmholtz Association –  comprises a wide range of single highly innovative discoveries/developments, with most of them still premature for application. Turning this strongly polarised opportunity/risk ratio into a sustainable innovation requires a high level of personal commitment in combination with entrepreneurial skills, where complex decision-making processes turn out to be obstructive.

Need for action has been recognized in these areas, and one can hope that the translation of results from fundamental university research into economic practice will further grow in efficiency, especially in a country
that highly depends on technological development.

First publication: Skerra, A., q&more, 2.2011.

Facts, background information, dossiers

  • intellectual proper…
  • early stage financing

More about TU München

  • News

    Enzyme system for the hydrogen industry

    An enzyme could make a dream come true for the energy industry: It can efficiently produce hydrogen using electricity and can also generate electricity from hydrogen. The enzyme is protected by embedding it in a polymer. An international research team with significant participation of scien ... more

    Artificial intelligence deciphers genetic instructions

    With the help of artificial intelligence (AI) a German-American team of scientists deciphered some of the more elusive instructions encoded in DNA. Their neural network trained on high-resolution maps of protein-DNA interactions uncovers subtle DNA sequence patterns throughout the genome, t ... more

    Synthetic “mini” receptors block atherosclerosis

    Atherosclerosis, a lipid-triggered chronic inflammatory disease of our arteries, is the main cause of strokes and heart attacks. An international team of researchers led by the Technical University of Munich (TUM) and the LMU University Hospital has developed novel synthetic peptides that c ... more

  • q&more articles

    Biobased raw material flows of the future

    Anthropogenic climate change and the rising world population, in combination with increasing urbanization, poses global challenges to our societies that can only be solved by technological advancement. The direct biotechnological use of greenhouse gases, including residual biomass flows fro ... more

    Taste and aroma boost in the mouth

    The food trend towards healthy snacks is continuing. Snacks made from freeze-dried fruit meet consumer expectations of modern and high-quality food. However, freeze drying of whole fruits requires long drying times and substantially reduces sensorial quality, which is unappealing to consumers. more

    Diet, gut microbiota and host lipid metabolism

    Nature provides an enormous diversity of lipid molecules that originate from various pathways. Fatty acids are key modules for various lipids, including cell membrane lipids such as phospholipids or triacylglycerols, which are the major components of lipid droplets. Excess lipids or defects ... more

  • Authors

    Prof. Dr. Thomas Brück

    Thomas Brück, born in 1972, obtained his B.Sc. in chemistry, biochemistry and management science from Keele University, Stoke on Trent. Additionally, he holds an M.Sc. in molecular medicine from the same institution. In 2002, Thomas obtained his Ph.D. in Protein Biochemistry from Imperial C ... more

    Dr. Norbert Mehlmer

    Norbert Mehlmer, born in 1977, studied biology at the University of Salzburg and wrote his diploma thesis at the Max Planck Institute for Molecular Genetics in Berlin. He earned his doctorate in genetics/microbiology at the Max F. Perutz Laboratories (MFPL) of the University of Vienna. Subs ... more

    Dr. Mahmoud Masri

    Mahmoud Masri accomplished his studies in Applied Chemistry at the University of Damascus and received his Master in 2010. He has been working as Quality Assurance Manager for five years. In 2019, he obtained his doctoral degree in biotechnology at the Technical University of Munich (TUM) w ... more

White paper

Product

Most widely read

  1. Weighing in the US Pharmacopeia
  2. Biobased raw material flows of the future
  3. Lean lab methods and safety in the laboratory
  4. Animal Venomics
  5. Drug substances in the drug product dossier
  6. Mercury in the environment
  7. Quality assurance in medical laboratories
  8. How GxP-regulated laboratories can use digitization as an opportunity
  9. Perspectives of Computer-Aided Drug Design
  10. Taste and aroma boost in the mouth

Topics A-Z

All topics

q&more – the networking platform for quality excellence in lab and process

The q&more concept is to increase the visibility of recent research and innovative solutions, and support the exchange of knowledge. In the broad spectrum of subjects covered, the focus is on achieving maximum quality in highly innovative sectors. As a modern knowledge platform, q&more offers market participants one-of-a-kind networking opportunities. Cutting-edge research is presented by authors of international repute. Attractively presented in a high-quality context, and published in German and English, the original articles introduce new concepts and highlight unconventional solution strategies.

> more about q&more

q&more is supported by:

 

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE